anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
RATIONALE: Cronkhite-Canada syndrome (CCS) is a nonhereditary, rare polyposis condition, first documented by Cronkhite and Canada in 1955. The primary distinct features of this syndrome include ectodermal abnormalities and diffuse gastrointestinal polyp changes accompanied by protein loss. The primary clinical manifestations of CCS include hair loss, excessive pigmentation of the skin, and malnourishment of fingernails or toenails. Other notable symptoms include weight loss, protein-losing enteropathy, diarrhea, abdominal pain, nausea, vomiting, taste abnormalities, and atrophic glossitis, which predominantly occur in middle-aged and older males. CCS is characterized by an extremely rare, nonfamilial hamartomatous polyposis syndrome, in which polyps are distributed in the stomach and colon (90%), small intestine(80%), and rectum (67%), while sparing the esophagus.
PATIENT CONCERNS: This report describes a 72-year-old female, initially treated for intestinal obstruction, followed by a small intestine resection. She reported diarrhea, emaciation, and loss of appetite across various hospitals.
DIAGNOSES: Endoscopic examination of the stomach and colon, plus capsule endoscopy, revealed multiple polyps throughout her gastrointestinal tract, except in the esophagus.
INTERVENTIONS: Treatment included hormones with antiallergic medication, acid-suppressing drugs, salicylates, and nutritional support with zinc sulfate, adding trace elements and amino acids.
OUTCOMES: posttreatment, the patient demonstrated significant improvement in appetite and taste. Atrophic glossitis, upper limb pigmentation, and frequency of diarrhea also notably decreased. reexamination through endoscopy after 3 months of treatment revealed a substantial decrease in the number and size of gastrointestinal polyps.
LESSONS: In this case, from the lower esophageal sphincter to the rectum, there is an increasing trend of eosinophil and mast cell infiltration. These lesions can cause a positive IgG result. Pathological analysis indicates that the extent and severity of lesions in the middle and lower gastrointestinal tract are more substantial than in the upper tract. During treatment, endoscopic observations reveal that lesions in the middle and lower tract tend to resolve faster than those in the upper tract. Hormone therapy has demonstrated significant efficacy in treating this disease. Early treatment and regular follow-up for this disease can reduce the risk of cancerous changes and related complications.
The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 6 hours, determined by randomization. At that point health care providers will manage active labor.
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive loss of somatic motor neurons. A major focus has been directed to motor neuron intrinsic properties as a cause for degeneration, while less attention has been given to the contribution of spinal interneurons. In the present work, we applied multiplexing detection of transcripts and machine learning-based image analysis to investigate the fate of multiple spinal interneuron populations during ALS progression in the SOD1G93A mouse model. The analysis showed that spinal inhibitory interneurons are affected early in the disease, before motor neuron death, and are characterized by a slow progressive degeneration, while excitatory interneurons are affected later with a steep progression. Moreover, we report differential vulnerability within inhibitory and excitatory subpopulations. Our study reveals a strong interneuron involvement in ALS development with interneuron specific degeneration. These observations point to differential involvement of diverse spinal neuronal circuits that eventually may be determining motor neuron degeneration.
We will investigate the clinical manifestations and molecular genetic defects of heritable connective tissue disorders, concentrating on the Marfan, Stickler, and Ehlers-Danlos syndromes. Although each of these conditions has been known for many years, the full spectrum of the associated phenotypes continues to be expanded and the genetic etiology of these conditions has not been completely elucidated. In addition, many patients have features overlapping two or more of the described syndromes, precluding unequivocal diagnosis. The goals of this study are to further define and characterize the full phenotype and natural history of these disorders, and to perform genetic linkage, gene identification, mutation detection, and genotype/phenotype correlations in affected individuals and families. Individuals suspected to have Marfan, Stickler or Ehlers-Danlos syndrome or a closely related disorder, as well as interested family members, will be enrolled. Participants will undergo genetic analyses and periodic clinical assessment. The expected outcomes will be improved clinical descriptions of the conditions and gene and mutation identification with analysis of genotype/phenotype correlations.
Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
BACKGROUND: MicroRNAs act as oncogenes or tumor suppressors in various cancers. The tumor microenvironment (TME) plays an important role in tumor cell progression and survival.
METHODS: MicroRNA expressions were evaluated by using NanoString nCounter assay, qRT-PCR and in situ hybridization. Correlation between MircoRNA expressions and TME factors, clinicopathological behaviors and prognostic significance were assessed in 323 surgically resected colorectal cancers.
RESULTS: The microRNA-206 expression was identified significantly higher in Glasgow microenvironment score (GMS) 0 than in GMS 1 or GMS 2 by using the NanoString nCounter assay and qRT-PCR. High microRNA-206 expression was identified in 155 (48.0 %) cases in in situ hybridization and was significantly correlated with low pT classification, and absence of lymphovascular and perineural invasion, and lymph node metastasis. MicroRNA-206 expression was significantly associated with low tumor stroma percentage (TSP), high Klintrup-Mäkinen (KM) grade and low GMS. Patients with high microRNA-206 expression showed significantly better 5-year overall survival than those with low microRNA-206 expression, and was an independent prognostic factor in patients with colorectal cancer. High miR-206 expression was associated with TME, favorable clinicopathologic behaviors and overall survival and presents an independent prognostic factor in patients with colorectal cancer.
CONCLUSION: Thus, MicroRNA-206 expression presents a feasible prognostic factor and potential therapeutic target to treat patients with colorectal cancer.
Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder ( e.g. , schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder,  etc. ) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent ( e.g. , an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
Although the efficacy of mechanical thrombectomy (MT) for acute basilar artery occlusion (ABAO) has been established in two randomized controlled studies, many patients have miserable clinical outcomes after MT for ABAO. Predicting severe disability prior to the procedure might be useful in determining the appropriateness of treatment interventions. Among the ABAO cases treated at 10 hospitals between July 2014 and December 2021, 144 were included in the study, all of whom underwent MRI before treatment. A miserable outcome was defined as a modified Rankin Scale (mRS) of 5-6 at 3 months. The associations between clinical, imaging, and procedural factors and miserable outcomes were evaluated. A miserable outcome was observed in 54 cases (37.5%). Multivariate analysis identified the National Institutes of Health Stroke Scale (NIHSS), transverse diameter of brainstem infarction, and symptomatic intracerebral hemorrhage as independent factors associated with miserable outcomes, with cutoff values of NIHSS 22 and transverse diameter of brainstem infarction 15 mm. Cases with a higher preoperative severity may result in miserable postoperative outcomes. Particularly, the transverse diameter of a brainstem infarction can be easily measured and serves as a useful criterion for determining treatment indications.
<P>PROBLEM TO BE SOLVED: To provide a gene construct, etc., useful for gene therapy for treating muscle-affecting diseases, including cardiovascular disorders.  <P>SOLUTION: This present invention concerns chimeric constructs comprising a skeletal α-actin gene promoter operably linked with at least a skeletal muscle- specific enhancer of a human gene. It also provides an expression cassette comprising such a chimeric construct to control expression of a gene of interest. The invention also relates to a vector, a viral particle, an eukaryotic host cell, a pharmaceutical composition each comprising the expression cassette and their use for specific expression in skeletal muscle cells as well as for therapeutic or prophylactic purposes. Finally, the present invention also provides the therapeutic use of an expression cassette, a vector and a viral particle comprising a gene of interest placed under the control of a skeletal α-actin gene promoter and a muscle-specific enhancer, especially for treating peripheral ischemia.  <P>COPYRIGHT: (C)2003,JPO
The invention belongs to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine plaster for treating colitis and a preparation method thereof. The medicine plaster is prepared from the following raw materials: angelica sinensis, codonopsis pilosula, red ginseng, notoginseng, costustoot, clove, saffron, turtle shell, netmeg, cortex cinnamomi, liquorice, white atractylodes rhizome, poria cocos, desertliving cistanche, dogwood, rhizoma coptidis, agastache rugosus, dandelion, radix bupleuri, hawthorn, asarum sieboldii, radix rehmanniae, prepared rhizome of rehmannia, rhubarb, pericarpium citri reticulatae, mangnolia officinalis, medicated leaven, the root of kudzu vine, sesame oil and yellow lead. The medicine plaster is prepared by taking the angelica sinensis, the codonopsis pilosula, the red ginseng, the notoginseng and the agastache rugosus as main medicines and the other components as assistant medicines. The medicine plaster is in an external application and internal treatment manner. The medicine plaster cannot hurt intestines and stomach no longer as well as cannot generate toxic and side effects and is applied conveniently. The medicine plaster has the obvious effects on treating acute and chronic colitis, proctitis, duodenal ulcer, anabrosis colitis, ulcerative enteritis, abdominal pain and diarrhea, dysentery excretion during shiting and the like.
A pharmaceutical agent containing a HBV(hepatitis B virus) neutralization human antibody, buffer, isotonic adjusting agent, and surfactant is provided to stabilize the antibody, and maintain the activity of antibody in a long time. A pharmaceutical agent comprises 0.1-50 mg/ml of human HBV(hepatitis B virus) neutralization antibody, 10-100 mmol/l of buffer, 20-250 mmol/l isotonic adjusting agent, and 0.001-1.0 weight% of surfactant. Antibody is a HBIG-Gene to HBV surface antigen which is produced from HBAb-49(KCLRF-BP-00054) cell line. The buffer is citrate salt, acetate salt, phosphate salt, or their free acid, base or salt or their mixture. The isotonic adjusting agent is sodium chloride, or potassium chloride. The surfactant is polyoxyethylene sorbitan fatty acid ester.
PURPOSE:To prepare an antiphlogistic and analgesic agent for external use in the form of gel, cream, ointment, poultice, etc., by adding a topicum base to a solution consisting of a pyrazolidine compound and a sufficient amount of peppermint oil or a salicylic acid ester to dissolve the compound. CONSTITUTION:The titled agent for external use can be prepared by adding a topicum base to a solution consisting of (A) a pyrazolidine compound (e.g.  phenylbutazone) and (B) at least one compound selected from peppermint oil,  methyl salicylate, ethyl salicylate, and salicylic acid monoglycol ester as a solvent of the component (A). Since the component (B) is a good solvent of the  component (A), there is no precipitation of crystals in the drug, and since the peppermint oil, etc. have assistant drug action as topicum in itself, the antiphlogistic and analgesic activity of the principal component can be further improved. The amount of the compoment (A) is 0.5-5wt%, and that of the component (B) is 4-20wt% for peppermint oil, or 2-15wt% for the other cases.
Vancomycin hydrochloride capsules, USP for oral administration contain chromatographically purified vancomycin hydrochloride, a tricyclic glycopeptide antibiotic derived from Amycolatopsis orientalis (formerly Nocardia orientalis), which has the chemical formula C66H75Cl2N9O24•HCl. The molecular weight of vancomycin hydrochloride is 1,485.73; 500 mg of the base is equivalent to 0.34 mmol. 

Each capsule contains 125 mg vancomycin (equivalent to 128 mg vancomycin hydrochloride) or 250 mg vancomycin (equivalent to 256 mg vancomycin hydrochloride). Inactive ingredient includes polyethylene glycol.

The 125 mg capsule shell contains gelatin, FD&C Blue No. 1, D & C Red No. 28, D & C Yellow No.10, titanium dioxide, iron oxide red and iron oxide yellow. The capsules are printed with black ink. The black imprinting ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide and potassium hydroxide. The 250 mg capsule shell contains gelatin, black iron oxide, iron oxide red, iron oxide yellow and titanium oxide. The capsules are printed with white ink. The white imprinting ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, potassium hydroxide and titanium dioxide.

Vancomycin hydrochloride has the structural formula:
This review discusses a broader scope of functional roles for NK cells. Despite the well-known cytolytic and inflammatory roles of NK cells against tumors and pathogenic diseases, extensive evidence demonstrates certain subsets of NK cells have defacto immunoregulatory effects and have a role in inducing anergy or lysis of antigen-activated T cells and regulating several autoimmune diseases. Furthermore, recent evidence suggests certain subsets of immunoregulatory NK cells can cause anergy or lysis of antigen-activated T cells to regulate hyperinflammatory diseases, including multisystem inflammatory syndrome. Several pathogens induce T cell and NK cell exhaustion and/or suppression, which impair the immune system's control of the replication speed of virulent pathogens and tumors and result in extensive antigens and antigen-antibody immune complexes, potentially inducing to some extent a Type III hypersensitivity immune reaction. The Type III hypersensitivity immune reaction induces immune cell secretion of proteinases, which can cleave specific proteins to create autoantigens which activate T cells to initiate autoimmune and/or hyperinflammatory diseases. Furthermore, pathogen induced NK cell exhaustion and/or suppression will inhibit NK cells which would have induced the anergy or lysis of activated T cells to regulate autoimmune and hyperinflammatory diseases. Autoimmune and hyperinflammatory diseases can be consequences of the dual lymphocyte exhaustion and/or suppression effects during infections, by creating autoimmune and/or hyperinflammatory diseases, while also impairing immunoregulatory lymphocytes which otherwise would have regulated these diseases.
A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
PURPOSE:A bathing agent contriving to effectively use decocted husk of oolong tea discharged in a large amount as an industrial waste from oolong tea industry, by subjecting decocted husk of oolong tea to rubbing processing, drying, further powdering to give powder and packing the powder in such a way that the powder can be decocted. CONSTITUTION:Decocted husk 1 of oolong tea is subjected to hand rubbing process or machine rubbing process 2 and well dried 3. Either natural drying or artificial drying may be used as the method of drying 3. Then the rubbed decocted husk of oolong tea is powdered 4 and packed 5 into a container 6 which is neither readily dissolved nor broken even if it is immersed in warm water to tive a bathing agent 9 which can be decocted. When the bathing agent 9 is added to a bathtub 8, the components of oolong tea are decocted by warm water 11 in the bathtub to give oolong tea bath, which has great effects such as keeping the bodywarm for a long time, to improve blood circulation in the body, etc. This bathing agent has merits of dissolving difficulty in treating a large amount of tea hust at a stroke.
Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter \[mg/dL\]). Once a participant achieves a stable ACSC (2-2.25 mmol/L \[8.0-9.0mg/dL\]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (\>) 2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be administered.
Campylobacter is the leading bacterial cause of infectious intestinal disease, but the pathogen typically accounts for a very small proportion of the overall stool microbiome in each patient. Diagnosis is even more difficult due to the fastidious nature of Campylobacter in the laboratory setting. This has, in part, driven a change in recent years, from culture-based to rapid PCR-based diagnostic assays which have improved diagnostic detection, whilst creating a knowledge gap in our clinical and epidemiological understanding of Campylobacter genotypes - no isolates to sequence. In this study, direct metagenomic sequencing approaches were used to assess the possibility of replacing genome sequences with metagenome sequences; metagenomic sequencing outputs were used to describe clinically relevant attributes of Campylobacter genotypes. A total of 37 diarrhoeal stool samples with Campylobacter and five samples with an unknown pathogen result were collected and processed with and without filtration, DNA was extracted, and metagenomes were sequenced by short-read sequencing. Culture-based methods were used to validate Campylobacter metagenome-derived genome (MDG) results. Sequence output metrics were assessed for Campylobacter genome quality and accuracy of characterization. Of the 42 samples passing quality checks for analysis, identification of Campylobacter to the genus and species level was dependent on Campylobacter genome read count, coverage and genome completeness. A total of 65% (24/37) of samples were reliably identified to the genus level through Campylobacter MDG, 73% (27/37) by culture and 97% (36/37) by qPCR. The Campylobacter genomes with a genome completeness of over 60% (n=21) were all accurately identified at the species level (100%). Of those, 72% (15/21) were identified to sequence types (STs), and 95% (20/21) accurately identified antimicrobial resistance (AMR) gene determinants. Filtration of stool samples enhanced Campylobacter MDG recovery and genome quality metrics compared to the corresponding unfiltered samples, which improved the identification of STs and AMR profiles. The phylogenetic analysis in this study demonstrated the clustering of the metagenome-derived with culture-derived genomes and revealed the reliability of genomes from direct stool sequencing. Furthermore, Campylobacter genome spiking percentages ranging from 0 to 2% total metagenome abundance in the ONT MinION sequencer, configured to adaptive sequencing, exhibited better assembly quality and accurate identification of STs, particularly in the analysis of metagenomes containing 2 and 1% of Campylobacter jejuni genomes. Direct sequencing of Campylobacter from stool samples provides clinically relevant and epidemiologically important genomic information without the reliance on cultured genomes.
The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
Women using hormone therapy (HT) are at an increased relative risk of venous thromboembolism (VTE). The frequency of inherited Factor V Leiden and other risk factors for VTE in the general population is estimated at 5-10%. This population has a 5-21 fold greater risk to develop VTE. Therefore, given the high thrombotic risk for the combination of hormone use and hereditary prothrombotic abnormalities these women's symptoms frequently go untreated for lack of alternative therapies. DT56a (Femarelle) is a soy derived compound that has been shown to act as a novel selective estrogen receptor modulator (SERM) in the alleviation of menopausal symptoms and prevention of postmenopausal bone loss without effecting the endometrium or the sex hormone blood profile. The research question of the current study is to assess the effect of femeralle on the coagulation system and determine if it is a reasonable and safe alternative for the treatment of menopausal symptoms in thrombophilic women.